Small Molecules
16 December 2013
Cubist Announces Positive Top-Line Results from Phase 3 Trial of Ceftolozane/Tazobactam in Intra-Abdominal Infections16 December 2013
Galapagos selects pre-clinical candidate for cystic fibrosis16 December 2013
FDA Grants Approval of IND to Commence a Phase 3 Pivotal Study for ST10 for the Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease16 December 2013
Hepatitis C: Phase III data show Boehringer Ingelheim’s faldaprevir* is effective even in patients with common drug-resistant viral variant14 December 2013
U.S. FDA Approves Gilead’s Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen13 December 2013
AstraZeneca announces top-line results from phase III monotherapy study of lesinurad in gout patients13 December 2013
FDA Issues Complete Response Letter for Canagliflozin/Metformin Fixed-Dose Combination Therapy for Type 2 Diabetes13 December 2013
Moberg Pharma Reports Positive Interim Results in Phase II Clinical Study of MOB-01513 December 2013
FDA Advisory Committee Recommends the Investigational SGLT2 Inhibitor Dapagliflozin for the Treatment of Type 2 Diabetes in Adults12 December 2013
An all-oral phase IIa study combining Simeprevir, TMC647055 and JNJ56914845 in hepatitis C patients to be initiated11 December 2013
Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery11 December 2013
Orexigen Resubmits Contrave New Drug Application11 December 2013
CytRx Reports Highly Statistically Significant Positive Results from its Global Phase 2b Clinical Trial11 December 2013
Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Meniere’s Disease11 December 2013
FDA Grants Priority Review for Genzyme’s Cerdelga™ (eliglustat), an Investigational Oral Therapy for Gaucher Disease10 December 2013
NewLink Genetics Initiates Phase 1 Clinical Trial of NLG919, a Novel Immune Checkpoint Inhibitor for Cancer Immunotherapy10 December 2013
Enanta Pharmaceuticals Announces 96 Percent SVR12 in Treatment Experienced Genotype 1 Hepatitis C Patients in SAPPHIRE-II Study10 December 2013
Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting10 December 2013
Spectrum Pharmaceuticals Announces Submission of New Drug Application for Belinostat, a novel pan-HDAC inhibitor10 December 2013
Verastem Initiates Clinical Trial of Dual mTOR/PI3K Inhibitor10 December 2013
Merck Advances Development Program for Investigational Alzheimer’s Disease Therapy, MK-8931News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports